Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

Inclusion Criteria: * Adult female, age ≥ 18 years. * Patient with cancer, requiring one of the following pre-specified chemotherapy regimen according to local guidelines: weekly paclitaxel, weekly docetaxel, eribuline or associationof weekly paclitaxel/docetaxel with carboplatine (association of targeted therapies not influencing significantly the risk of alopecia is allowed, i.e. trastuzumab, pertuzumab or bevacizumab). * Healthy hair (no current alopecia or scalp disease treatment). * Life expectancy ≥ 6 months. * Able to use the study treatment in compliance with the protocol. * Physical and psychological ability to participate. * Negative serum pregnancy test within 14 days prior to randomization in premenopausal women with childbearing potential. * Patients must agree to not shave their head (minimum ≥ 1 cm). * Signed and dated informed consent. Exclusion Criteria: * Other ongoing anti-neoplastic therapy or other investigational drug with potential effect on hair growth. * Patients treated with proteasome inhibitors, i.e. bortezomib. * Prior radiotherapy to the scalp with residual alopecia. * Known allergy or hypersensitivity to some components of CG 428 cutaneous solution (including allium cepa (onion), citrus, caffeine, theobromine). * Pre-existing alopecia or significant scalp disease, which may alter study treatment administration or absorption. * Concomitant use of cold cap or any other anti-hair loss treatment. * Hair transplants.